ASH Clinical Practice Guidelines on Diagnosis and Treatment of Amyloidosis

Over recent years, growing knowledge and advances in diagnostic approaches have enhanced the recognition of light chain (AL) amyloidosis. The purpose of these guidelines is to provide evidence-based recommendations to facilitate early and accurate diagnosis of AL amyloidosis. A second panel covering the treatment of AL amyloidosis will follow.

Amyloidosis is a rare group of disorders caused by protein misfolding. In North America, one of the common forms of amyloidosis is light chain amyloidosis (AL). These guidelines are intended to support patients, clinicians, and other health care professionals in their decisions about the diagnosis and treatment of AL.

Guideline Implementation Tools and Resources

Disease State Infographic

Visual Summary

This concise visual aid is intended to support understanding of the recommendations and to aid in clinical decision-making:

Teaching Slides

These educational slides are intended to teach about diagnosis of amyloidosis.

Quality Metrics Assessment Tool

This set of metrics is intended to assess compliance with the ASH Clinical Practice Guidelines on Diagnosis of Light Chain Amyloidosis. Use this tool to identify quality gaps at your institution and improve care for patients with light chain amyloidosis.

Pocket Guide

This brief, evidence-based pocket guide is intended to help physicians provide quality care to patients.

Podcasts

In this episode of Heme Talks, we are joined by Dr. Sai Jambunathan as she shares her experiences with the diagnosis and management of a rare blood disorder known as AL amyloidosis. As a patient herself, listeners will gain insights into the complex initial workup and what the treatment journey is like for patients with this condition. Our patient advocate episodes highlight the importance of advocacy, community, and shared understanding between patients and their healthcare providers.